TRU 015

Drug Profile

TRU 015

Alternative Names: PF-5212374; TRU-015

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Pfizer; Trubion Pharmaceuticals; Wyeth
  • Class Antineoplastics; Antirheumatics; Peptides
  • Mechanism of Action Apoptosis stimulants; B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Canada (IV)
  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in European Union (IV)
  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Mexico (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top